Apteka Exhibition Russian Health Care Week UFI Approved Event
To main
For exhibitors
For visitors

ViewPoints: Will Roche plot broader subcutaneous strategy for US market


Earlier this week, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favour of Roche’s subcutaneous version of Rituxan. With the agency scheduled to make an approval decision by June 26, the signs are positive. Given the overwhelmingly positive nature of Wednesday’s AdCom, analysts think Roche may now look to develop subcutaneous versions of other key oncology brands for the US market, as it has done in Europe.

Source: firstwordpharma.com

Back to the list

Invite partners to the exhibition
Facebook Youtube RSS Feed

Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34